Format

Send to

Choose Destination
See comment in PubMed Commons below
Ther Adv Chronic Dis. 2012 Jul;3(4):173-81. doi: 10.1177/2040622312446244.

Oral renin inhibitors in clinical practice: a perspective review.

Author information

  • 1Department of Internal Medicine, Ospedale dell'Angelo-General Hospital, Mestre-Venezia, Italy.

Abstract

Hypertension is an important risk factor for cardiovascular morbidity and mortality. The importance of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular and renal diseases has long been recognized: for this reason the conventional therapies, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), β-blockers, and aldosterone antagonists represent the backbone of current antihypertensive therapy. Aliskiren is the first direct renin inhibitor (DRI) suitable for oral administration. By achieving more complete renin-angiotensin system inhibition, direct renin inhibitors may afford greater protection from hypertensive complications. Present evidence indicates that aliskiren reduces baseline systolic and diastolic blood pressure greater than placebo and that it is as effective as other first-line antihypertensive agents. Extra advantages can be reached when it is used in combination therapy. Clinical trials and in vitro studies also suggest that aliskiren has several cardioprotective and renoprotective effects. Therapy with aliskiren is well tolerated, but recently some concerns have arisen because of the early termination of the ALTITUDE study due to an increased incidence of adverse effects.

KEYWORDS:

aliskiren; direct renin inhibition; hypertension; renin–angiotensin–aldosterone system

PMID:
23342233
PMCID:
PMC3539287
DOI:
10.1177/2040622312446244
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center